Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors

Yuji Ikari, Yuya Matsue, Sho Torii, Misaki Hasegawa, Kazuki Aihara, Shunsuke Kuroda, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Takuya Kishi, Issei Komuro, Ken Ichi Hirata, Koichi Node, Shingo Matsumoto

研究成果: Article査読

抄録

Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19). Methods and Results: In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. Conclusions: This study suggests the potential benefits of statins use against COVID-19.

本文言語English
ページ(範囲)939-943
ページ数5
ジャーナルCirculation Journal
85
6
DOI
出版ステータスPublished - 2021

ASJC Scopus subject areas

  • 循環器および心血管医学

フィンガープリント

「Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル